David Bearss
Co-Founder, Chief Executive Officer & President Halia Therapeutics
Seminars
Wednesday 28th January 2026
Unlocking Genetic Resilience: Preventing Alzheimer’s in APOE4 Carriers with HT-4253
3:45 pm
- Harnessing Genetic Resilience: Halia Therapeutics leverages insights from naturally occurring protective genetic variants to discover new therapeutic pathways that mimic resilience and prevent age-related disease
- The APOE4 Case Study: APOE4 is the strongest genetic risk factor for Alzheimer’s disease. Halia’s approach focuses on identifying resilience mechanisms that allow some APOE4 carriers to remain cognitively intact into old age
- HT-4253 as a Proof of Concept: Our drug, HT-4253, represents the first therapeutic candidate developed from this resilience framework, targeting innate immune dysfunction and neuroinflammation associated with APOE4 risk
- A Platform for Broader Impact: By systematizing resilience discovery, Halia is pioneering a new model for drug development, shifting from treating late-stage disease to intercepting pathology early in genetically high-risk populations
